top of page



In addition to her strong educational background in sciences related to pharmaceuticals, Dr. Linck has extensive experience in the pharmaceutical area, including as a Vice President and then Senior Vice President, Intellectual Property, Regulatory Affairs & Chief Compliance Counsel, at Guilford Pharmaceuticals; as an Administrative Patent Judge at the USPTO in the pharmaceutical and biotechnology group; as Deputy General Counsel, IP & Trade, at the Biotechnology Innovation Organization; and as a consultant and expert witness in numerous Hatch-Waxman cases and antitrust cases based on earlier Hatch-Waxman cases.   


Dr. Linck has extensive experience relating to patent matters in the computer-related technology area. In her role as Solicitor, she represented the USPTO in a number of computer-related technology litigation matters between 1994 and 1998 and was a primary author of the first set of USPTO Computer-Related Guidelines. Since then, she has consulted on and served as an expert witness in this technology area.


Dr. Linck has extensive experience consulting on AIA proceedings in the USPTO, particularly post-grant proceedings and on related federal court litigation. She is a co-author of one of the first major AIA treatises addressing AIA practice, titled Post-Grant Patent Practice (published by the Bureau of National Affairs in 2012, 2014 and 2016). She also taught a course at University of San Diego Law Center, dedicated to AIA practices.


Dr. Linck has extensive experience consulting on all aspects of USPTO practice, including serving as the Solicitor of Patents and Trademarks and as an Administrative Patent Judge.  As Solicitor, she had responsibility for all legal matters in the USPTO, including USPTO rule-making, overseeing the Office of Enrollment and Discipline, and all legal guidelines issued by the USPTO. She has testified before Congress, the FTC, and DOJ regarding USPTO patent practices and has worked through professional organizations to improve those practices.

bottom of page